Press releases

May 17, 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more
May 07, 2024

Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference

Read more
May 02, 2024

Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update

Read more
April 30, 2024

Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease

Read more
April 30, 2024

Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

Read more
April 25, 2024

Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update

Read more
April 19, 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more
April 15, 2024

Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102

Read more
April 12, 2024

Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome

Read more
April 12, 2024

Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting

Read more